>
Switch to:

Altamira Therapeutics Debt-to-EBITDA

: 0.00 (As of Jun. 2021)
View and export this data going back to 2014. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Altamira Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2021 was $0.00 Mil. Altamira Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2021 was $0.00 Mil. Altamira Therapeutics's annualized EBITDA for the quarter that ended in Jun. 2021 was $-14.47 Mil. Altamira Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2021 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Altamira Therapeutics's Debt-to-EBITDA or its related term are showing as below:

NAS:CYTO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.94   Med: -0.41   Max: -0.04
Current: -0.04

-0.94
-0.04

During the past 10 years, the highest Debt-to-EBITDA Ratio of Altamira Therapeutics was -0.04. The lowest was -0.94. And the median was -0.41.

NAS:CYTO's Debt-to-EBITDA is ranked lower than
99.99% of the 27 Companies
in the Biotechnology industry.

( Industry Median: 1.85 vs. NAS:CYTO: -0.04 )

Altamira Therapeutics Debt-to-EBITDA Historical Data

The historical data trend for Altamira Therapeutics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altamira Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Debt-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.41 -0.45 -0.14 - -0.07

Altamira Therapeutics Semi-Annual Data
Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
Debt-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -0.01 -0.05 -

Competitive Comparison

For the Biotechnology subindustry, Altamira Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Altamira Therapeutics Debt-to-EBITDA Distribution

For the Biotechnology industry and Healthcare sector, Altamira Therapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Altamira Therapeutics's Debt-to-EBITDA falls into.



Altamira Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Altamira Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2020 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.58982440342188 + 0) / -9.0792435839712
=-0.06

Altamira Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2021 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -14.472350738048
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2021) EBITDA data.


Altamira Therapeutics  (NAS:CYTO) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Altamira Therapeutics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Altamira Therapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Altamira Therapeutics Business Description

Altamira Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 541714 SIC : 2834
Traded in Other Exchanges
Address
8 The Green, Suite 12455, Dover, DE, USA, 19901
Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens.

Altamira Therapeutics Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)